We are initiating coverage of Curaleaf Holdings (TSX, OTC) with a “Buy” rating. Curaleaf’s strengths, especially its strategic international expansion, outweigh its challenges. We believe that further legalization in key states and regulatory progress in Europe will drive the company’s growth.
Strengths of Curaleaf Compared to Its Peers
Curaleaf has a significant market presence, operating in 17 U.S. states and expanding internationally. Its strong retail network and diverse product offerings give it a competitive edge. Strategic acquisitions, like Can4Med, enhance its distribution in Europe, positioning it well for future growth. Its revenue mix shows a strong retail segment, supported by over 900 wholesale partner accounts, highlighting robust market penetration and efficiency.
Weaknesses of Curaleaf Compared to Its Peers
Curaleaf faces challenges with its current ratio, which is below both…
